Posted by Michael Wonder on 24 Jan 2017
EMA validates Gilead’s marketing authorisation application for investigational chronic hepatitis C therapy sofosbuvir/velpatasvir/voxilaprevir
20 January 2017 - Sofosbuvir with velpatasvir and voxilaprevir granted an accelerated assessment by the EMA.
Gilead Sciences today announced that the company’s marketing authorisation application for the investigational, once-daily, single tablet regimen of sofosbuvir 400 mg, velpatasvir 100 mg and voxilaprevir 100 mg for the treatment of chronic hepatitis C virus infected patients has been fully validated and is now under assessment by the EMA.
